Teleflex Incorporated (TFX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several positive factors: increased revenue growth guidance, improved adjusted gross margins, and strong performance in the Vascular Intervention business. The Q&A session further supports this with positive insights on market share growth and successful integration of acquisitions. Although cash flow from operations decreased, the overall financial outlook and strategic plans, including a focus on maximizing shareholder value through a potential sale, suggest a positive sentiment. The upward revision of guidance and strong market performance indicate a likely positive stock price movement in the short term.
Key Financial Performance
Third Quarter Revenues $913 million, an increase of 19.4% year-over-year on a GAAP basis. Adjusted revenues were $892.9 million, up 16.8% year-over-year on a reported basis and up 15.3% on an adjusted constant currency basis. The increase was driven by operational excellence and the acquired Vascular Interventions business.
Adjusted Earnings Per Share $3.67, a 5.2% increase year-over-year. The increase was due to higher revenue, adjusted operating income, a lower tax rate, and share count, partially offset by higher interest expense and foreign exchange impacts.
Americas Revenues $555.9 million, a 7.5% increase year-over-year. Growth was driven by the acquired Vascular Intervention business and strength in Surgical, Interventional, and Vascular businesses, partially offset by OEM declines and challenges in UroLift.
EMEA Revenues $214.1 million, a 34.4% increase year-over-year. Growth was driven by the Vascular Intervention acquisition and strength in Surgical, Vascular, and Interventional businesses, partially offset by anesthesia business declines and decreased military orders.
Asia Revenues $122.9 million, a 25.3% increase year-over-year. Growth was driven by the Vascular Intervention acquisition and a $9 million stocking order for intra-aortic balloon pump and catheter growth strategy in China, partially offset by volume-based procurement.
Vascular Access Revenue $191 million, a 4.3% increase year-over-year. Growth was driven by the broad Vascular Access portfolio, including peripheral access, EZ-IO, and central access products.
Interventional Revenue $266.4 million, a 76.4% increase year-over-year. Excluding the Vascular Intervention acquisition, revenues increased 9% year-over-year. Growth was led by intra-aortic balloon pump catheters, OnControl, and complex catheters.
Anesthesia Revenue $101.4 million, a 1.4% decrease year-over-year. Decline was due to decreased military orders and softness in tracheostomy tubes, partially offset by growth in ET tubes, LMA single-use masks, and hemostatic products in the U.S.
Surgical Revenue $122.9 million, an 8.8% increase year-over-year. Growth was led by chest drainage and instrumentation, partially offset by volume-based procurement in China.
Interventional Urology Revenue $71.8 million, a 14.1% decrease year-over-year. Decline was due to pressure on UroLift, partially offset by strong double-digit growth for Barrigel.
OEM Revenue $80.4 million, a 3.9% decrease year-over-year. Decline was driven by customer inventory management, though there was a sequential revenue increase compared to the previous quarter.
Other Revenue $59 million, a 3.1% increase year-over-year. Growth was broad-based across the portfolio.
Adjusted Gross Margin 57.3%, a 350 basis point decrease year-over-year. Decline was due to tariffs, foreign exchange rates, product mix, and increased logistics and distribution costs.
Adjusted Operating Margin 23.3%, a 400 basis point decrease year-over-year. Decline was due to gross margin pressure, higher operating expenses from the Vascular Intervention acquisition, and foreign exchange impacts.
Adjusted Net Interest Expense $29.7 million, compared to $18.8 million in the prior year period. Increase was due to borrowings for the Vascular Intervention acquisition.
Adjusted Tax Rate 9.1%, compared to 13.6% in the prior year period. Decrease was due to beneficial tax provisions from the One Big Beautiful Bill Act and other nonrecurring discrete impacts.
Cash Flow from Operations (9 months) $189 million, compared to $435.6 million in the prior year period. Decrease was due to unfavorable changes in working capital, payments for tariffs, separation-related costs, and foreign tax payments.
Cash and Cash Equivalents $381.3 million at the end of the third quarter, compared to $327.7 million at year-end 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Freesolve resorbable magnesium scaffold: BIOMAG-II trial reached midpoint ahead of schedule with over 1,000 patients enrolled. Data readout expected in 2027.
Barrigel: Launched in Japan during Q3 2025, targeting prostate cancer treatment. First cases performed in August, with training programs for adoption.
Geographic revenue growth: Americas revenue increased 7.5%, EMEA revenue grew 34.4%, and Asia revenue rose 25.3% year-over-year, driven by Vascular Intervention acquisition and other product strengths.
Barrigel expansion: Launched in Japan, marking a significant milestone in global expansion.
Restructuring activities: Planned workforce reductions and relocation of manufacturing operations to lower-cost locations, expected to complete by 2028.
Operational efficiencies: Focus on cost controls and tariff mitigation strategies, reducing estimated tariff impact for 2025.
Separation of Teleflex: Progress on separating into RemainCo and NewCo, with a potential sale of NewCo prioritized to maximize shareholder value.
Vascular Intervention business: Integration activities on track, achieving 6.9% year-over-year revenue growth in Q3 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Separation of Teleflex into two companies: The separation process into RemainCo and NewCo could lead to operational disruptions, challenges in strategic execution, and potential inefficiencies during the transition period. Additionally, the sale of NewCo, while generating proceeds, may introduce uncertainties in market positioning and operational focus for both entities.
Italian payback measure: The Italian payback measure, which requires manufacturers to pay back excess costs to the government, poses financial risks. Although recent legislative changes reduced the amount owed, this regulation could still impact future revenue and financial stability in the region.
Intra-aortic balloon pump revenue decline: Lower-than-expected order rates for intra-aortic balloon pumps, particularly in the U.S., have led to a $30 million reduction in revenue expectations for 2025. This decline could impact overall financial performance and market share.
Foreign exchange rates: Negative impacts of foreign exchange rates have contributed to decreased gross and operating margins, posing a challenge to maintaining profitability.
Tariffs and logistics costs: Tariffs and increased logistics and distribution costs have negatively impacted gross margins, adding financial pressure to the company.
UroLift performance: Continued challenges in the UroLift business, with a 14.1% revenue decline, indicate ongoing market or operational issues that could hinder growth in the Interventional Urology segment.
Military orders and anesthesia business: Decreased military orders and softness in tracheostomy tubes have negatively impacted the anesthesia business, contributing to a 1.4% revenue decline in this segment.
Customer inventory management in OEM: OEM revenue decreased by 3.9% due to customer inventory management, reflecting potential demand fluctuations and operational inefficiencies.
Restructuring and workforce reductions: Planned restructuring activities, including workforce reductions and relocation of manufacturing operations, may lead to short-term operational disruptions and employee morale issues.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Separation of Teleflex into Two Companies: Teleflex is advancing the separation into two independent companies, RemainCo and NewCo. The process prioritizes a potential sale of NewCo, with healthy interest reported. The separation aims to create focused strategic directions, simplified operations, and tailored capital allocation strategies for each entity.
Intra-aortic Balloon Pump Revenue: Revenue expectations for intra-aortic balloon pumps have been reduced by $30 million at the midpoint of 2025 guidance due to lower-than-expected order rates, particularly in the U.S. This trend is expected to continue through Q4 2025.
2025 Adjusted Revenue Growth: Adjusted revenue growth for 2025 is now expected to be in the range of 8% to 8.5%, revised from the prior guidance of 8.5% to 9.5%. This reflects updated expectations for Q4 2025 and includes the acquired Vascular Intervention business.
Foreign Exchange Impact: A positive foreign exchange impact of $32 million is expected for 2025, representing a 100 basis point tailwind to GAAP revenue growth.
Adjusted Gross Margin and Operating Margin: For 2025, adjusted gross margin is expected to be approximately 59%, and adjusted operating margin is projected to be approximately 24.5%.
Adjusted Earnings Per Share (EPS): The adjusted EPS guidance for 2025 has been narrowed to $14 to $14.20, reflecting updated revenue and margin expectations.
Vascular Intervention Business Performance: The Vascular Intervention business achieved 6.9% year-over-year reported revenue growth in Q3 2025, modestly exceeding guidance. The business is expected to generate $204 million in revenue for the second half of 2025.
Barrigel Launch in Japan: Barrigel was launched in Japan in Q3 2025, targeting the prostate cancer market. The product aims to enhance treatment precision and reduce radiation exposure for patients undergoing therapy.
Tariff Mitigation Strategies: Tariff impact for 2025 has been revised to $25-$26 million, an improvement from the previous estimate of $29 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Value Maximization: The company is committed to maximizing shareholder value through the separation of Teleflex into two independent companies, RemainCo and NewCo. This includes a potential sale of NewCo.
Capital Allocation Strategy: Proceeds from the potential sale of NewCo will be used to balance debt paydown and return capital to shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the comments regarding balloon pumps in China?
A:The company observed a $9 million stocking order from distributor customers due to two reasons: 1) Expansion of the intra-aortic balloon growth strategy driven by government changes recommending the use of intra-aortic balloon pumps and catheters for complex PCI procedures. 2) Customer behavior changes due to market noise with tariffs, leading to purchasing ahead of tariffs as tenders are delayed. The situation is expected to normalize in Q4.
Q:Is there a risk of losing market share in the stent and balloon business to newer drug-coated balloons in the U.S. and Europe?
A:Management stated that drug-coated balloons have been in the European market longer than in the U.S., and drug-coated stents are still used alongside them. The performance of their drug-coated stents was in line with expectations, and BIOTRONIK is growing at almost 7%, which is encouraging for the acquired Vascular Intervention business.
Q:Is the spin-off of NewCo off the table, and why is the company prioritizing a sale?
A:The company is prioritizing the sale of NewCo due to significant buyer interest and progress in the sale process. While a spin-off is still considered a shareholder value creation strategy, the sale is seen as the best way to maximize shareholder value at this stage. The company is in late stages of diligence with multiple buyers.
Q:What is the dollar amount of the fourth quarter revenue guidance?
A:The implied Q4 revenue guidance is $930 million to $945.6 million, representing a 14% to 15.8% constant currency growth, with a $21 million FX tailwind.
Q:Can you update on the margin range and tariff exposure of RemainCo and NewCo?
A:There hasn't been significant change to the margins of RemainCo or NewCo outside of tariff impacts. Tariff data and pump impacts have been disclosed to potential buyers of NewCo. The tariff environment is somewhat improving and more stable.
Q:Do you need additional flagship products in the vascular business to accelerate growth?
A:Management believes they do not need additional flagship products to achieve growth goals. The interventional business is performing well, with BIOTRONIK growing almost 7% and the underlying interventional business growing around 9%. The company plans to release new products, invest in R&D, and consider M&A opportunities.
Q:What is the growth outlook for the stapling system in the bariatrics segment?
A:The stapling system grew in the upper single digits in the quarter and is expected to continue growing. However, the growth rate is lower than originally planned, leading to a write-down in intangible assets.
Q:Are there any updates on the potential sale of NewCo?
A:The company is focused on selling the entirety of NewCo and is in the later stages of due diligence with multiple buyers. The sale is prioritized over a spin-off to maximize shareholder value.
Q:What is the long-term outlook for intra-aortic balloon pumps and catheters?
A:The intra-aortic balloon pump market is a $250 million annual market. The company has increased its market share significantly in the U.S. Catheters are expected to continue being a growth driver for several years, with strong double-digit growth in Q3.
Q:How is the integration of the BIOTRONIK Vascular business progressing?
A:The integration is going well, with rock-solid employee retention and no loss of senior leadership. The team is robust, especially in technical and R&D capabilities, and is contributing to the company's interventional portfolio.
Q:What is the outlook for procedure volumes in the cath lab?
A:Procedure volumes in the cath lab are stable to improving, with good solid upper single-digit growth in the company's portfolio. The cath lab is seen as a healthy area with stable growth.
Q:Are there early wins in expanding reach in EMEA with the BIOTRONIK Vascular business?
A:While there are some anecdotal early wins, it is too early to call it a trend. The integration and restructuring are focused on back-office areas and some commercial organization adjustments.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of buyers or the exact progress of the NewCo sale process. Additionally, they did not provide detailed updates on the restructuring and headcount reductions in the sales force, stating only that it involves back-office areas and some commercial adjustments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Act
BIOMAG II
Intervention acquisition
Intervention expectation
Interventional
Japan
NewCo
Teleflex
UroLift
Vascular Intervention
Vascular business
activity
assumption
balance
balloon pump
basis Vascular
cancer
comparison
currency
decrease
end
exchange rate
government
increase Vascular
interest
margin
measure year
order
patient
payback measure
payment
press release
process
reserve
restructuring
revenue increase
tax
TFX Transcript
Teleflex Incorporated (TFX) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call highlights strong revenue growth across segments and a strategic focus on innovation, with increased R&D investment. The company's guidance for 2026 shows optimism, particularly with planned divestitures and share repurchases. Despite some integration disruptions, the long-term outlook appears strong. The Q&A suggests analysts are generally satisfied, with no significant concerns raised. The company's refusal to provide quarterly guidance is offset by expected growth acceleration in the latter half of 2026. Overall, the strategic actions and financial outlook support a positive sentiment.
Teleflex Incorporated (TFX) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents mixed signals: a positive shareholder return plan with significant share repurchases, strong EPS growth, and successful product launches. However, concerns arise from the reduced revenue guidance, increased expenses, and unclear future growth plans. The Q&A session highlighted uncertainties in management's responses and potential risks from tariff impacts. These mixed factors balance each other out, leading to a neutral sentiment prediction for stock price movement.
Teleflex Incorporated (TFX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-18
Teleflex Incorporated (TFX) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlights several positive factors: increased revenue growth guidance, improved adjusted gross margins, and strong performance in the Vascular Intervention business. The Q&A session further supports this with positive insights on market share growth and successful integration of acquisitions. Although cash flow from operations decreased, the overall financial outlook and strategic plans, including a focus on maximizing shareholder value through a potential sale, suggest a positive sentiment. The upward revision of guidance and strong market performance indicate a likely positive stock price movement in the short term.
TFX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
